Canada’s official federal health service has released a warning about potential complications surrounding the gout medication Uloric. The Canadian Uloric warning has stirred concern in the United States over the potential risk of these effects manifesting in American patients.
Explaining The Canadain Uloric Warning
The Canadian Uloric warning concerned the standard 80 mg tablet of Uloric, also known generically as febuxostat. According to the notice, a study was conducted by CARES to examine the cardiovascular risk in patients who took Uloric with preexisting conditions. The preexisting conditions included were:
- A history of major cardiovascular disease
- Tendency for cerebrovascular disease
- Diabetes mellitus with microvascular disease
- Diabetes mellitus with macrovascular disease
The Cares study found a higher incidence of cardiovascular deaths in users of Uloric when compared to and alternative gout treatment known as allopurinol. With 3,098 patients who used Uloric and 3,092 patients who used allopurinol, 74.4% more patients died of cardiovascular complications while taking Uloric (134 out of 3,098) as opposed to allopurinol (100 out of 3,092). It was also noted that most of the cardiovascular deaths in the Uloric group were caused by Sudden Heart Death (SDC), in which the heart spontaneously loses functionality.
That Canadian Uloric warning issued a set of guidelines alongside the announcement of the study results to reduce the dangers posed by these conclusions. Healthcare professionals have been advised to only prescribe Uloric to adult patients who have a negative response or intolerance to allopurinol, deny Uloric prescription to patients who have tendencies favoring heart attacks, ischemic heart disease, or congestive heart failure, and monitor patients for signs of heart attack, stroke, or heart failure in patients taking Uloric.
For more information about the risks and complications of Uloric visit Parker Waichman’s Uloric Lawsuit Lawyers Page.
How The Canadian Uloric Warning Affects Your Compensation
While the Canadain Uloric warning does not directly affect policy in the United States. The warnings and trials in other countries can serve as warnings to consumers globally. As with previous complications such as textured breast implants and breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), the Canadian Uloric warning may serve to pique FDA and consumer interest in examining this potential risk.
If you or a loved one have experienced cardiovascular injury or wrongful death while using Uloric, the Canadien Uloric may help you earn compensation. No publication or study can be more important, however, that choosing the right law firm. The right law firm should be one with a winning record, experience in defective drug litigation, and the resources to take on large corporations. The right law firm should be PArker Waichman LLP.
At Parker Waichman LLP, experienced teams of trial attorneys will pursue your case to its utmost extent to earn you the compensation you deserve to recover from your injuries. Contact Parker Waichman today for a free consultation and being your journey to justice today.
New York | Brooklyn | Queens | Long Island | New Jersey | Florida
Call us at: 1-800-YOURLAWYER (800-968-7529) | Schedule your free consultation